Helus
Business Services · United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.helus.comRevenue
$14.8 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Helus
Helus Pharma is a pharmaceutical company focused on developing next-generation therapies for mental health. Publicly traded on the NASDAQ and CBOE CA under the ticker HELP, the company leverages a proprietary drug development platform to create novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. Its work includes lead drug programs such as HLP003 and HLP004, with clinical trials evaluating CYB004 for the treatment of generalized anxiety disorder. The company develops novel delivery formulations intended to support consistent administration and reduce variability of acute effects for patients.Explore more
Helus Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Helus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Helus recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Helus had a recent Job posting/layoffs
Helus, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Helus
Check if Helus has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Helus launches new products
Check out if Helus is spiking on competitors!
Funding: Get notified immidiatlly once Helus has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Helus
Find 2 more new buyers
Company Profile Activity
Activity Insights
Helus is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Helus is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Helus.
Helus Tech Stack
A closer look at the technologies used by Helus
See more technologies
Most Recent Scoops
Person-Based
Project
reported Phase 2 results for CYB003 showing a 13 to 14-point improvement on the MADRS Depression Scale after three weeks and one dose, with no drug-related serious adverse events, durability data extending to 12 months, and a second dose producing an additional 5-point MADRS improvement, alongside 100% response rates and remission rates exceeding 70%.
Medical Research, Pharmaceuticals
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Pharmaceuticals, Clinical Operations
Project
Pharmaceuticals, Clinical Operations
Helus News & Media
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -Helus Pharma Appoints Michael Halstead as Chief Executive Officer
Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & JohnsonHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM ProgramBig Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
Issued on behalf of Helus Pharma™ Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Helus
Sign Up For FreeTo access detailed company insights
Helus Pharma is a pharmaceutical company focused on developing next-generation therapies for mental health. Publicly traded on the NASDAQ and CBOE CA under the ticker HELP, the company leverages a proprietary drug development platform to create novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways... Read More
